Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model

Osteolytic bone disease is a hallmark of multiple myeloma (MM) mediated by MM cell proliferation, increased osteoclast activity, and suppressed osteoblast function. The proteasome inhibitor bortezomib targets MM cells and improves bone health in MM patients. Radium-223 dichloride (radium-223), the f...

Descripción completa

Detalles Bibliográficos
Autores principales: Suominen, Mari I., Mäki-Jouppila, Jenni, Huhtinen, Anna, Sjöholm, Birgitta, Rissanen, Jukka P., Luostarinen, Anniina, Fagerlund, Katja M., Alhoniemi, Esa, Siemeister, Gerhard, Mumberg, Dominik, Käkönen, Sanna-Maria, Scholz, Arne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197539/
https://www.ncbi.nlm.nih.gov/pubmed/34070363
http://dx.doi.org/10.3390/ijms22115570

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197539/
https://www.ncbi.nlm.nih.gov/pubmed/34070363
http://dx.doi.org/10.3390/ijms22115570

Ejemplares similares